+44 1223 804200 info@spherefluidics.com
Single cells

Encapsulating Biology
Transforming Discovery

Our novel analytical instrumentation and collaborative research services enable the rapid screening and characterisation of single cells and their biological products for use in research, biotherapeutic discovery, bioproduction, cell therapy engineering, drug discovery and diagnostics.

If you’re searching for rare and valuable variants within large cell populations, we can help you do it faster, more cost-effectively and with a greater chance of success.

Life Sciences Research & Development Applications

With flexible, future-proofed technologies we boost assay throughput and sensitivity, reduce consumable usage and optimise discovery, development and bioproduction across a broad range of applications.

Biopharmaceuticals and antibody production

Biopharmaceutical Discovery and Development

Increase the throughput and speed of your R&D pipeline. Better characterise biotherapeutic products. Carry out effective cell sorting & retrieval. And find those ‘one in a billion’ variants.

Read More

Synthetic biology

Bioproduction (Synthetic Biology)

Rapidly screen large libraries to sort through diverse populations of bacteria, yeast, hybridomas and transformed cells to find the best clones.

Read More

Cell therapy engineering, analysis and isolation

Cell Therapy Engineering, Analysis and Isolation

Develop, analyse and select cells for therapeutic applications, such as using engineered T-Cells for cell therapy.

Read More

Drug discovery and biotherapeutics

Single Cell Disease Research

Carry out in-depth studies into infectious diseases, cancer and autoimmune disease through the effective compartmentalisation and analysis of single cells from disease-related samples.

Read More

Metagenomic analyses

Metagenomics

Use our systems to carry out comprehensive metagenomic analyses that probe deeper into complex conditions, such as metabolic disorders and poorly defined diseases.

Read More

Single cell diagnostics

Single Cell Diagnostics and Prognostics

Our technology is an effective tool for purifying complex clinical samples and analysing single cells to improve patient diagnosis and better predict prognosis.

Read More

Lorem Ipsum Dolor Sit Amet

Lorem ipsum dolor sit amet, sit soluta aliquam at, minim virtute eu per. Nec ne duis reque iriure, et tota novum facilisi usu, principes constituam qui ea. Mel aperiri vocibus cu, no eos saperet prodesset. Quo populo disputando ut. Per suas complectitur no, vel in viris quando qualisque. Et wisi graeco habemus eam, in nulla assentior mnesarchum mel, ne his nominavi partiendo.

Soluta deterruisset nam ei, esse sanctus consulatu ad pro. Legere graece vis ne, has ut ludus facilisi. Ea eos principes assentior, mei nibh maiorum minimum ad. His id nibh dolore, pro percipitur consequuntur cu, eos consequat adipiscing id.

Technology

Our technology makes it possible to screen billions of cells and provides you with the best chance of finding that rare and valuable variant.

How do we do this? With microfluidic technology that allows the ultra-high throughput analysis of isolated single cells in miniaturised (pL to nL) volumes, picodroplets.

We offer a number of systems, from industrial solutions designed for ‘plug and play’ use, through to more customised research instruments and research services for use in laboratories with more specialised needs. Our range of cost-effective consumables is specifically designed to work harmoniously with our instruments, providing significant time, cost and energy savings when used together.

Our technology and expertise is applied with our novel workflows to aid the discovery and development of therapeutics from single cells. Whether it’s for short research projects, technology development programmes or partnerships, we provide a range of specialist collaborative services to suit your needs. Together we can reduce the cost and complexity of your research, and increase the speed of your discoveries.

Sphere Fluidics, UCL and University of Liverpool Publish Microfluidics Paper on Novel Label-Free Nanoparticle Characterisation Method

Dr David Holmes (Principal Engineer at Sphere Fluidics) and collaborators at University College London and University of Liverpool have just published a paper in the international journal Electrophoresis. The title of the paper is: “Real-time dielectrophoretic signalling and image quantification methods for evaluating electrokinetic properties of nanoparticles.” Dr Holmes commented: “We have developed novel methods that enable robust and accurate measurements of the electrokinetic properties of ultra-small volumes of biological molecules (e.g. DNA, RNA, proteins) and cells.”

The article was published in Electrophoresis and can be found here.

Sphere Fluidics Nominated as a Finalist in UKBAA Angel Investment 2015 Awards

Sphere Fluidics has been nominated as a Finalist in the UK Business Angel Association 2015 Angel Investment Award for “Best Investment – High Growth Manufacturing”. “We already have over 140 customers for our UK-manufactured consumable products” said Dr Frank F. Craig (CEO). “We recently closed a £1.8 million angel investment round to help us now develop high value instrumentation systems, such as Cyto-Mine – our novel high-throughput single cell analysis system. Via market research we have identified over 2,000 potential users of this product. We are now manufacturing our first Cyto-Mines.” Event info can be found here.